share_log

Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter

Benzinga Real-time News ·  Oct 20, 2021 08:18
  • The FDA has granted Sesen Bio Inc's (NASDAQ:SESN) request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer.
  • Related: Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch. 
  • The CMC Type A Meeting has been scheduled for October 29.
  • The Company is also preparing for a separate Type A meeting to discuss the recommendations specific to additional data and analyses raised in the CRL. 
  • The Company expects the Clinical Type A Meeting to happen later in Q4 of 2021. 
  • Also Read: Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: SESN shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment